One-shot gene therapy aims to free patients from endless eye injections
Disease control
Ongoing
This study is observing the long-term safety and effectiveness of a one-time gene therapy injection for wet age-related macular degeneration (AMD), a leading cause of blindness. It follows 23 people for up to 10 years after they received the therapy in a previous trial. The goal …
Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC